Effectiveness of antimalarial drugs

New England Journal of Medicine

Volumn 352, Issue 15, 2005, Pages

  Baird, J Kevin ^a,b  

^a US Naval Medical Research Unit No 2 Jakarta   (Indonesia)

^b American Embassy Jakarta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN; ARTESUNATE; ARTESUNATE PLUS FANSIDAR; ARTESUNATE PLUS MEFLOQUINE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; FANSIDAR; HALOFANTRINE; MEFLOQUINE; NEW DRUG; ORAL CONTRACEPTIVE AGENT; PRIMAQUINE; PROGUANIL; QUININE; TETRACYCLINE; UNCLASSIFIED DRUG; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

AFRICA; ANOREXIA; ANTIBIOTIC RESISTANCE; ANXIETY DISORDER; COMA; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEARING IMPAIRMENT; HEART ARREST; HEART PALPITATION; HEMOLYTIC ANEMIA; HUMAN; IMMUNITY; INSOMNIA; KIDNEY FAILURE; MALARIA; MONOTHERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; PUBLIC HEALTH; QT PROLONGATION; QUALITY CONTROL; RESPIRATORY ARREST; REVIEW; RURAL AREA; SOUTHEAST ASIA; STEVENS JOHNSON SYNDROME; STOMATITIS; TINNITUS; TOXICITY; TREATMENT OUTCOME; VERTIGO; VIVID DREAM; VOMITING; ANIMAL; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; GROWTH, DEVELOPMENT AND AGING; LIFE CYCLE; PLASMODIUM; RECURRENT DISEASE; TREATMENT FAILURE;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LIFE CYCLE STAGES; MALARIA; MEFLOQUINE; PATIENT COMPLIANCE; PLASMODIUM; PRIMAQUINE; PYRIMETHAMINE; QUININE; RECURRENCE; SULFADOXINE; TREATMENT FAILURE;

EID: 16844376016     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra043207     Document Type: Review

References (119)

1. Trigg PI, Kondrachine AV. Commentary: malaria control in the 1990s. Bull World Health Organ 1998;76:11-6.
2. Roberts DR, Laughlin LL, Hsheih P, Legters LJ. DDT, global strategies, and a malaria control crisis in South America. Emerg Infect Dis 1997;3:295-302.
3. Curtis CF. Should the use of DDT be revived for malaria vector control? Biomedica 2002;22:455-61.
4. Baird JK. Resurgent malaria at the millennium: control strategies in crisis. Drugs 2000;59:719-43.
5. Guerin PJ, Olliaro P, Nosten F, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2002;2:564-73.
6. Attaran A, Barnes KI, Curtis C, et al. WHO, the Global Fund, and medical malpractice in malaria treatment Lancet 2004;363:237-40.
7. Goodman C, Kachur SP, Abdulla S, et al. Retail supply of malaria-related drugs in rural Tanzania: risks and opportunities. Trop Med Int Health 2004;9:655-63.
8. Arrow KJ, Panosian C, Gelband H, eds. Saving lives, buying time: economics of malaria drugs in an age of resistance. Washington, D.C.: National Academies Press, 2004:12.
9. Muller O, Traore C, Becher H, Kouyate B. Malaria morbidity, treatment-seeking behavior, and mortality in a cohort of young children in rural Burkina Faso. Trop Med Int Hlth 2003;8:290-6.
10. Deressa W, Ali A, Enqusellassi F. Self-treatment in rural communities, Butajira, southern Ethiopia. Bull World Health Organ 2003;81:261-8.
11. Fungladda W, Honrado ER, Thimasam K, et al. Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ 1998;76:Suppl 1:59-66.
12. Duarte EC, Gyorkos TW. Self-reported compliance with last malaria treatment and occurrence of malaria during follow-up in a Brazilian Amazon population. Trop Med Int Health 2003;8:518-24.
13. Okonkwo PO, Akpala CO, Okafor HU, Mbah AU, Nwaiwu O. Compliance to correct dose of chloroquine in uncomplicated malaria correlates with improvement in the condition of rural Nigerian children. Trans R Soc Trop Med Hyg 2001;95;320-4.
14. White NJ. Antimalarial drug resistance. J Clin Invest 2004;113:1084-92.
15. Basco LK. Molecular epidemiology of malaria in Cameroon XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg 2004;70:245-50.
16. Newton P, Proux S, Green M, et al. Fake artesunate in southeast Asia. Lancet 2001;357:1948-50.
17. Newton PN, White NJ, Rozendaal JA, Green MD. Murder by fake drugs. BMJ 2002;324:800-1.
18. Minzi OM, Moshi MJ, Hipolite D, et al. Evaluation of the quality of amodiaquine and sulfadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam, Tanzania. J Clin Pharm Ther 2003;28:117-22.
19. White NJ, Krishna S. Treatment of malaria: some considerations and limitations of the current methods of assessment. Trans R Soc Trop Med Hyg 1989;83:767-77.
20. Day NPJ, Pham TD, Phan TL, et al. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood 1996;88:4694-700.
21. White NJ. Why is it that antimalarial drug treatments do not always work? Ann Trop Med Parasitol 1998;92:449-58.
22. Ittarat W, Pickard AL, Rattanasinganchan P, et al. Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg 2003;68:147-52.
23. Bolaji OO, Sadare IO, Babalola CP, Ogunbona FA. Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol 2002;58:543-5.
24. McGready R, Stepniewska K, Seaton E, et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 2003;59:553-7.
25. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004;27:25-61.
26. Health information for international travel, 2003-2004. Atlanta: Centers for Disease Control and Prevention, 2003:99-116.
27. Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf 1996;14:131-45.
28. Wernsdorfer WH. Coartemether (artemether and luemfantrine): an oral antimalarial drug. Expert Rev Anti Infect Ther 2004;2:181-96.
29. Mayxay M, Newton PN, Khanthavong M, et al. Chloroquine versus sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum malaria in Savannakhet Province, Lao People's Democratic Republic: an assessment of national antimalarial drug recommendations. Clin Infect Dis 2003;37:1021-8.
30. Djimde AA, Doumbo OK, Traore O, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 2003;69:558-63.
31. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994;169:932-5.
32. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 1996;55:243-9.
33. Trape JF, Pison G, Preziosi MP, et al. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 1998;321:689-97.
34. Zucker JR, Ruebush TK II, Obonyo C, Otieno J, Campbell CC. The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg 2003;68:386-90.
35. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001;64(Suppl 1-2):97-106.
36. Maguire JD, Sumawinata IW, Masbar S, et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002;360:58-60.
37. Collins WE, Jeffery GM. Extended clearance time after treatment of infections with Plasmodium malariae may not be indicative of resistance to chloroquine. Am J Trop Med Hyg 2002;67:406-10.
38. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002;2:209-18.
39. Wernsdorfer WH, Noedl H. Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr Opin Infect Dis 2003;16:553-8.
40. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001;184:770-6.
41. Pickard AL, Wongsrichanalai C, Purfield A, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 2003;47:2418-23.
42. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997;176:1590-6.
43. Schwobel B, Alifrangis M, Salanti A, Jelinek T. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphism in the cytochrome b as potential in vivo resistance marker. Malar J 2003;2:5.
44. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization, 2003.
45. Coatney GR, Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 1963;12:121-8.
46. Wezam A. Plasmodium falciparum sensitivity to antimalarials at Humera, north-western Ethiopia. Ethiop Med J 1993;31:271-6.
47. Ghalib HW, Al-Ghamdi S, Akood M, Haridi AE, Ageel AA, Abdalla RE. Therapeutic efficacy of chloroquine against uncomplicated Plasmodium falciparum malaria in south-western Saudi Arabia. Ann Trop Med Parasitol 2001;95:773-9.
48. Warsame M, Abdillahi A, Duale ON, et al. Therapeutic efficacy of chloroquine and sulfadoxine/pyrimethamine against Plasmodium falciparum infection in Somalia. Bull World Health Organ 2002;80:704-8.
49. Kebede F, Taffa N, Tedla T. An in-vivo study of falciparum malaria sensitivity to Chloroquine in unstable malaria endemic area of central Ethiopia. Ethiop Med J 1999;37:97-109.
50. Al-Maktari MT, Bassiouny HK. Malaria status in Al-Hodeidah Governate, Republic of Yemen. Part II. Human factors causing the persistence of chloroquine resistant P. falciparum local strain. J Egypt Soc Parasitol 2003;33:829-39.
51. Dev V, Phookan S, Barman K. Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India. Ann Trop Med Parasitol 2003;97:783-91.
52. Shah I, Rowland M, Mehmood P, et al. Chloroquine resistance in Pakistan and the upsurge of falciparum malaria in Pakistani and Afghan refugee populations. Ann Trop Med Parasitol 1997;91:591-602.
53. Rab MA, Freeman TW, Durrani N, de Poerck D, Rowland MW. Resistance of Plasmodium falciparum malaria to chloroquine is widespread in eastern Afghanistan. Ann Trop Med Parasitol 2001;95:41-6.
54. Singh N, Mishra AK, Shukla MM, Chand SK. Forest malaria in Chhindwara, Madhya Pradesh, central India: a case study in a tribal community. Am J Trop Med Hyg 2003;68:602-7.
55. Mohapatra PK, Namchoom NS, Prakash A, Bhattacharya DR, Goswami BK, Mahanta J. Therapeutic efficacy of antimalarials in Plasmodium falciparum malaria in an Indo-Myanmar border area of Arunachal Pradesh. Indian J Med Res 2003;118:71-6.
56. Rahman MR, Paul DC, Rashid M, et al. A randomized controlled trial on the efficacy of alternative treatment regimens for uncomplicated falciparum malaria in a multi-drug-resistant falciparum area of Bangladesh - narrowing the options for the National Malaria Control Programme? Trans R Soc Trop Med Hyg 2001;95:661-7.
57. Rowland M, Durrani N, Hewitt S, Sondorp E. Resistance of falciparum malaria to chloroquine and sulfadoxine-pyrimethamine in Afghan refugee settlements in western Pakistan: surveys by the general health services using a simplified in vivo test. Trop Med Int Health 1997;2:1049-56.
58. Fryauff DJ, Baird JK, Candradikusuma D, et al. Survey of in vivo sensitivity to chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia. Am J Trop Med Hyg 1997;56:241-4.
59. Zhang ZX, Li CZ, Huang GZ, et al. Assessment of therapeutic efficacy of chloroquine against falciparum malaria in an outbreak area in Xishuangbanna, Yunnan. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2002;20:94-7.
60. al-Yaman F, Genton B, Mokela D, Narara A, Raiko A, Alpers MP. Resistance of Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990-1993. P N G Med J 1996;39:16-22.
61. Schwobel B, Jordan S, Vanisaveth V, et al. Therapeutic efficacy of chloroquine plus sulphadoxine/pyrimethamine compared with monotherapy with either chloroquine or sulfadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos. Trop Med Int Health 2003;8:19-24.
62. Smithuis FM, Monti F, Grundl M, et al. Plasmodium falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar. Trans R Soc Trop Med Hyg 1997;91:468-72.
63. Sumawinata IW, Leksana B, Sutamihardja A, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003;68:416-20.
64. Maguire JD, Lacy MD, Sismadi P, et al. Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, Plasmodium falciparum malaria during an epidemic in Central Java, Indonesia. Ann Trop Med Parasitol 2002;96:655-68.
65. Lokman Hakim S, Sharifah Roohi SW, Zurkurnai Y, et al. Plasmodium falciparum: increased proportion of severe resistance (RII and RIII) to chloroquine and high rate of resistance to sulfadoxine-pyrimethamine in Peninsular Malaysia after two decades. Trans R Soc Trop Med Hyg 1996;90:294-7.
66. Bustas DG, Canfield CJ, Canete-Miguel E, Hutchinson DB. Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine- pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999;179:1587-90.
67. Baird JK, Tiwari T, Martin GJ, et al. Chloroquine for the treatment of uncomplicated malaria in Guyana. Ann Trop Med Parasitol 2002;96:339-48.
68. Marquino W, MacArthur JR, Barat LM, et al. Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru. Am J Trop Med Hyg 2003;68:120-3.
69. Caraballo A, Rodriguez-Acosta A. Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela. Am J Trop Med Hyg 1999;61:120-4.
70. Llanos-Cuentas A, Campos P, Clendenes M, Canfield CJ, Hutchinson DB. Atovaquone and proguanil or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in Peru. Braz J Infect Dis 2001;5:67-72.
71. Blair S, Lopez ML, Pineros JG, Alvarez T, Tobon A, Carmona J. Therapeutic efficacy of 3 treatment protocols for non-complicated Plasmodium falciparum malaria, Antioquia, Colombia, 2002. Biomedica 2003;23:318-27. (In Spanish.)
72. Looareesuwan S, Wilairatana P, Krudsood S, et al. Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol 1999;93:225-30.
73. Baird JK. Resistance to chloroquine by Plasmodium vivax. Antimicrob Agents Chemother 2004;48:4075-83.
74. Lwin M, Aung S, Kyaw MP, et al. A simplified in vivo drug sensitivity test for malaria in the field. Southeast Asian J Trop Public Health 1997;28:247-53.
75. Tjitra E, Suprianto S, Currie BJ, Morris PS, Saunders JR, Anstey NM. Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. Am J Trop Med Hyg 2001;65:309-17.
76. Tjitra E, Suprianto S, Anstey NM. Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine- pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance. Trans R Soc Trop Med Hyg 2002;96:434-7.
77. Ejov MN, Tun T, Aung S, Sein K. Response of falciparum malaria to different antimalarials in Myanmar. Bull World Health Organ 1999;77:244-9.
78. Fryauff DJ, Sumawinata I, Richie TL, et al. In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gagisland off northwest Man Jaya, Indonesia. Am J Trop Med Hyg 1999;60:542-6.
79. Fryauff DJ, Leksana B, Masbar S, et al. The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia. Ann Trop Med Parasitol 2002;96:447-62.
80. van den Broek IV, Gatkoi T, Lowoko B, Nzila A, Ochong E, Keus K. Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated Plasmodium falciparum malaria in Upper Nile, south Sudan. Trans R Soc Trop Med Hyg 2003;97:229-35.
81. Ezard N, Nellepalli P, Asha AW. Sulfadoxine-pyrimethamine remains efficacious against uncomplicated Plasmodium falciparum malaria in north-eastern Afghanistan. Ann Trop Med Parasitol 2004;98:85-8.
82. Blair-Trujillo S, Lacharme-Lora L, Carmona-Fonseca J. Resistance of Plasmodium falciparum to antimalarial drugs in Zaragoza (Antioquia, Colombia), 1998. Mem Inst Oswaldo Cruz 2002;97:401-6.
83. Gonzalez IJ, Padilla JO, Giraldo LE, Saravia NG. Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Narino, Colombia, 1999-2002. Biomedica 2003;23:38-46. (In Spanish.)
84. Blair S, Lacharme LL, Fonseca JC, Tobon A. Resistance of Plasmodium falciparum to 3 antimalarials in Turbo (Antioquia, Colombia), 1998. Rev Panam Salud Publica 2001;9:23-9. (In Spanish.)
85. Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, et al. Drug-resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian J Trop Med Public Health 2001;32:41-9.
86. Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield CJ, Hutchinson DB. Efficacy and safety of atovaquone/proguanil compared to mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999;60:526-32.
87. Hopperus BAP, van Thiel PP, Lobel HO, et al. Long-term chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996;173:1506-9.
88. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:963-72.
89. Lobel HO, Varma JK, Miani M, et al. Monitoring for mefloquine-resistant Plasmodium falciparum in Africa: implications for travelers' health. Am J Trop Med Hyg 1998;59:129-32.
90. Marquino W, Huilca M, Calampa C, et al. Efficacy of mefloquine and a mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru. Am J Trop Med Hyg 2003;68:608-12.
91. Avila JC, Villaroel R, Marquino W, Zegarra J, Mollinedo R, Ruebush TK. Efficacy of mefloquine and mefloquine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon region of Boliva. Trop Med Int Health 2004;9:217-21.
92. Schlagenhauf P, Tschopp A, Johnson R, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double-blind, four arm study. BMJ 2003;327:1078-84.
93. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001;33:1015-21.
94. van Riemsdijk MM, Sturkenboom MC, Ditters JM, Ligthelm RJ, Overbosch D, Stricker BH. Atovaquone plus proguanil versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002;72:294-301.
95. van Riemsdijk MM, Ditters JM, Sturkenboom MC, et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 2002;58:441-5.
96. van Rjmesdijk MM, Sturkenboom MC, Ditters JM, et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 2004;57:506-12.
97. Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF. Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Am J Trop Med Hyg 1998;58:630-7.
98. McGready R, Brockman A, Cho T, et al. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2000;94:689-93.
99. Pukrittayakamee S, Waniwimolruk S, Stepniewska K, et al. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated malaria. Antimicrob Agents Chemother 2003;47:3458-63.
100. Ache A, Escorihuela M, Vivas E, et al. In vivo drug resistance of falciparum malaria in mining areas of Venezuela. Trop Med Int Health 2002;7:737-43.
101. Roche J, Guerra-Neira A, Raso J, Benito A. Surveillance of in vivo resistance of Plasmodium falciparum to antimalarial drugs from 1992 to 1999 in Malabo (Equatorial Guinea). Am J Trop Med Hyg 2003;68:598-601.
102. Demar M, Carme B. Plasmodium falciparum in vivo resistance to quinine: description of two RIII responses in French Guiana. Am J Trop Med Hyg 2004;70:125-7.
103. Bunnag D, Karbwang J, Na-Bangchang K, Thanavibul A, Chittamas S, Harinasuta T. Quinine-tetracycline for multidrug resistant falciparum malaria. Southeast Asian J Trop Med Public Health 1996;27;15-8.
104. Taylor WR, Rjchie TL, Fryauff DJ, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999;28:74-81.
105. Denis MB. Improving compliance with quinine + tetracycline for treatment of malaria: evaluation of health education interventions in Cambodian villages. Bull World Health Organ 1998;76:Suppl 1:43-9.
106. Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003;37:1659-67.
107. Baird JK, Wiady I, Sutanihardja A, et al. Therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparam in northeastern Papua, Indonesia. Am J Trop Med Hyg 2002;66:659-60.
108. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004;39:1336-45.
109. Arnold J, Alving AS, dayman. CB, Hochwald RS. Induced primaquine resistance in vivax malaria. Trans R Soc Trop Med Hyg 1961;55:345-50.
110. Peters W. Drag resistance in malaria - a perspective. Trans R Soc Trop Med Hyg 1969;63:25-45.
111. White NJ. Antimalarial drag resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 1999;354:739-49.
112. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Am J Trop Med Hyg 1999;60:533-54.
113. Kremsner PG, Krishna S. Antimalarial combinations. Lancet 2004;364:285-94.
114. Adjuik M, Babiker A, Gamer P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004;363:9-17.
115. Lim P, Chim P, Sem R, et al. In vitro activities of artesunate, mefloquine and other drugs against Plasmodium falciparum isolates in Cambodia: proceedings of the International Symposium on Malaria Control in the Mekong Region, Siem Reap, Cambodia. Mekong Malar Forum 2002;10:49-51.
116. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand; a prospective study. Lancet 2000;356:297-302.
117. Wongsrichanalai C, Prajakwong S, Meshnick SR, Shanks GD, Thimasarn K. Mefloquine-its 20 years in the Thai malaria control program. Southeast Asian J Trop Med Public Health 2004;35:300-8.
118. Awad MI, Alkadru AMY, Behrens RH, Baraka OZ, Eltayeb IB. Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan. Am J Trop Med Hyg 2003;68;153-8.
119. Barnes KI, Mwenechanya J, Tembo M, et al. Efficacy of rectal artesunate compared with patenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study. Lancet 2004;363:1598-605.